SNAP Message Board - Msg: 929930

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNAP

SNAP 7.900

-1.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (9)	3/5/1997 9:37:00 AM
From: Dr. John M. de Castro	of 124

SNAP announced that a patent for the NPY-5 Receptor issued a short while ago. This was quietly announced by SNAP and had no effect on the market. This is typical of the quiet, no hype, competence of this company. Because of this "just the facts" approach, there are few wild oscillations in the stock price. Also since other biotechs hype incessantly SNAP has been little noticed and way undervalued. The NPY-5 receptor patent is potentially very valuable. NPY is a transmitter in the brain that is the most potent molecule known to elicit eating. NPY plays other roles in the brain. But, the eating effects appear to be mediated via the NPY-5 receptor. SNAP and others have provided an array of compelling evidence that this NPY-5 receptor is one of the most important in the nervous system for the control of eating. Given all the hype regarding Leptin and the obesity gene "du jour", the NPY story has gone relatively unnoticed. However, IMO: the evidence to date suggests that this is the best potential route for affecting appetite control pharmacologically. Hence, this patent may seem like a small plus for SNAP. In fact it may be a major factor in the development of truely effective obesity therapeutics. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next